Skip to main content
Fig. 4 | Journal of Ovarian Research

Fig. 4

From: TTK is a potential therapeutic target for cisplatin-resistant ovarian cancer

Fig. 4

TTK activated PI3K/AKT signaling pathway. A RNA-seq results showed the top 10 differential genes between A2780cis cells with and without TTK knockdown. B The expression levels of p-AKT/AKT and p-PI3K/PI3K in A2780cis were higher than in A2780 cells, and their expression could be reduced when TTK was down-regulated in A2780cis cells. C A2780cis cells were treated with cisplatin and TTK inhibitor. (a) The phosphorylation levels of PI3K and AKT were inhibited using TTK inhibitor. (b) TTK inhibitor suppressed cell proliferation. D A2780cis cells were treated with cisplatin and PI3K inhibitor. (a) PI3K inhibitor would reduce the phosphorylation of PI3K and AKT without affecting TTK expression. (b) PI3K inhibitor suppressed cell proliferation. ***P < 0.001

Back to article page